News – Page 973 – Endpoints News

Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

7 years ago

Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly

7 years ago

How much does it cost to hire a top Big Pharma exec to run a biotech? Here are 4 (very) fresh examples

7 years ago

Atara seeks new CEO as Isaac Ciechanover exits; AstraZeneca's Mark Mallon tapped to replace Peter Hecht at Ironwood

7 years ago

Aimmune enters into loan agreement with KKR; Boehringer bags rights to second RNAi drug from Dicerna

7 years ago

Scoop: MedImmune chief Bahija Jallal is leaving AstraZeneca and joining the trek into biotech

7 years ago

Joining forces with Skyhawk, C4 Therapeutics, Biogen buys more shots on goal on SMA, Alzheimer's

7 years ago

Celgene sweetened the pot for exec team ahead of Bristol-Myers merger announcement

7 years ago

Deserted by Takeda, Mersana abandons lead drug

7 years ago

A biotech startup breaks a 3-year silence, displaying a $65M raise and a next-gen approach to PARP

7 years ago

Axing staff and shelving cancer programs, Selecta hopes laser focus on gout will prove a way out

7 years ago

Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market

7 years ago

Deal-hungry Verily secures $1B in fresh funding, months after pressing pause on smart lens project

7 years ago

Juno founders set their sights on creating an ‘epic’ new biotech with high-rolling investors at their back

7 years ago

Sanofi sharpens focus on mRNA for cancer with equity investment in Germany's BioNTech

7 years ago

Jazz triggers Codiak’s first exosome alliance with a $76M ante and up to $1B-plus in milestones

7 years ago

Vertex beefs up gene-editing work with new discovery pact; Verrica shares jump on molluscum drug data; J&J's inks two ...

7 years ago

After blueprinting R&D hub, AbbVie dishes out $105M for CD39 pact with Tizona's new CEO from Roche

7 years ago

Takeda builds arsenal for immuno-oncology research, creates cell therapy group

7 years ago

With early-stage studies underway, Connect Biopharmaceuticals closes $55M round to advance immune modulators

7 years ago

Gene silencing company NeuBase Therapeutics to reverse merge its way onto Nasdaq via troubled microcap Ohr

7 years ago

Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline

7 years ago

Merck goes all-in on a late-stage NASH drug from NGM as development race heats up

7 years ago

Why did Liz Barrett turn her back on a top job at Novartis in exchange for the helm of a biotech you never heard of?

7 years ago

First page Previous page 970 971 972973974 975 976 Next page Last page